The Muscular Dystrophy Drugs Market was valued at USD 2.13 billion in 2025 and is projected to reach USD 35.61 billion by 2033, growing at a CAGR of 42.20% from 2026 to 2033. The market is experiencing consistent growth driven by rising prevalence of muscular dystrophy disorders, increasing demand for targeted and innovative treatment options, and continuous advancements in gene therapy, molecular therapies, and precision medicine approaches. The growing focus on rare disease research, improved diagnostic capabilities, and increasing healthcare investments are encouraging pharmaceutical companies and biotechnology firms to develop advanced therapies for muscular dystrophy patients.
7 weergaven